Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Accumulated Expenses (2018 - 2025)

Historic Accumulated Expenses for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $42.5 million.

  • 10x Genomics' Accumulated Expenses rose 324.3% to $42.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $42.5 million, marking a year-over-year increase of 324.3%. This contributed to the annual value of $42.5 million for FY2025, which is 324.3% up from last year.
  • Per 10x Genomics' latest filing, its Accumulated Expenses stood at $42.5 million for Q4 2025, which was up 324.3% from $37.1 million recorded in Q3 2025.
  • In the past 5 years, 10x Genomics' Accumulated Expenses registered a high of $62.0 million during Q3 2022, and its lowest value of $32.7 million during Q1 2021.
  • Over the past 5 years, 10x Genomics' median Accumulated Expenses value was $42.5 million (recorded in 2024), while the average stood at $44.4 million.
  • As far as peak fluctuations go, 10x Genomics' Accumulated Expenses soared by 8597.37% in 2021, and later plummeted by 4151.22% in 2023.
  • Quarter analysis of 5 years shows 10x Genomics' Accumulated Expenses stood at $50.9 million in 2021, then grew by 17.42% to $59.8 million in 2022, then fell by 5.24% to $56.6 million in 2023, then decreased by 27.33% to $41.2 million in 2024, then grew by 3.24% to $42.5 million in 2025.
  • Its last three reported values are $42.5 million in Q4 2025, $37.1 million for Q3 2025, and $39.1 million during Q2 2025.